The AMC trial was difficult to interpret, given the unusual dosing of rituximab, use of obsolete antiretroviral combinations, and inclusion of patients with severe immunodeficiency (with CD4+ cell counts <50/mm3). The gene discussed is CD4; the disease is Immunodeficiency.